The products and services are deployed through the ObvioGo platform and app and increase compliance and retention in clinical trials.
Deployed through ObvioHealth’s ObvioGo platform and app, these products and services increase compliance and retention in clinical trials and deliver more accurate and real-time data.
The purpose-built ObvioGo app uses behavioral science insight into participants’ digital behaviors. It has a friendly interface that incorporates reminders, alerts, task progress bars, and gamification.
The UX-optimized ePRO tools will shorten and simplify questionnaires at every turn and often allow for answer submissions with just one thumb tap.
Besides questionnaires, the AI-enabled digital instruments of ObvioGo allow participants to capture and submit photos, videos, and audio files.
This data will be automatically transferred to expert raters for scoring and provide more objective outcomes to sponsors.
The ObvioGo platform also integrates with remote patient monitoring devices that include a range of AI-enabled, medical-grade sensors and over 300 consumer wearables.
The ObvioHealth patient engagement suite’s fourth component is its Clinical Oversight and Coordination Hub (Coach).
It consists of registered nurses, clinical trial specialists, and principal investigators and is accessible to each participant through text, call, video, email, or other messaging applications such as WeChat or WhatsApp. Patients will be able to select different methods of communication within the ObvioGo app.
ObvioHealth CEO Ivan Jarry said: “Not only does ObvioGo include truly innovative, patient-centric tech but also the personalised support of our COACH team to radically improve the experience for our patients.
“Our team is enabled by artificial intelligence, which streamlines their workflows, allowing them to provide high-touch support for a truly differentiating clinical trial journey.”
In September this year, ObvioHealth introduced a next-generation decentralised clinical trial (DCT) platform and mobile application called ‘ObvioGo’ to provide robust therapeutic efficacy and safety evidence.
